Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 6/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | MELK | Q14680 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14489815 | 0.84 | GPR119 (0.47) | ERBB2EGFRCHRM4 | |
| SCHEMBL14489819 | 0.84 | EGFR (0.49) | ERBB2EGFRPIK3CDPIK3CAMTNR1B | |
| SCHEMBL5567844 | 0.82 | ERBB2 (0.58) | ERBB2EGFR | |
| SCHEMBL5564230 | 0.82 | EGFR (0.55) | ERBB2EGFR | |
| SCHEMBL5569914 | 0.82 | EGFR (0.53) | ERBB2EGFRPIK3CDPIK3CAMTNR1B | |
| SCHEMBL1446657 | 0.82 | EGFR (0.59) | ERBB2EGFR | |
| SCHEMBL5564929 | 0.82 | PIK3CD (0.51) | ERBB2PIK3CDPIK3CAPIK3CBPIK3CG | |
| Hydrochloric Acid SCHEMBL5564704 | 0.81 | ERBB2 (0.57) | ERBB2EGFR | |
| SCHEMBL1527983 | 0.81 | EGFR (0.47) | ERBB2EGFRMTNR1BCHRM4 | |
| Hydrochloric Acid SCHEMBL4967454 | 0.80 | EGFR (0.46) | ERBB2EGFRMTNR1BCHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| EP-1664028-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026151-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ABL1, ERBB2, LCK | ERBB2 2/4885EGFR 15/4885PIK3CD 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.